Pioneering tomorrow's therapeutics
through glycan engineering.
Our mission
The next generation of therapeutics.
kyron.bio unlocks superior protein therapeutics by harnessing the power of glycan modifications.
Our novel engineering strategy precisely controls glycosylation patterns, opening a new era of antibody therapeutics.
This has the power to deliver better therapies and transform patient outcomes.
Read more about
Our people
are dedicated to revolutionising the way we make therapeutic drugs
TEAM
Dr. Emilia McLaughlin
CEO & FOUNDER
Sabine da Silva
EXECUTIVE ASSISTANT
Dr. Marina Lochhead
HEAD OF R&D
Floriane Bitaudeau
LAB ENGINEER
Dr. Damien Toullec
LAB MANAGER
Salomé Guez
RESEARCH ASSOCIATE
Dr. Caroline Desmurget
SENIOR SCIENTIST
Proudly supported by
We would love to hear from you
and leading angel investors.
News
%20Press%20Release%20-%20kyron_bio%20(59_4%20x%2042%20cm).png)
2026
kyron.bio Announces Strategic Partnership with Servier to Advance Precision Glycosylation in Antibody Therapeutics.
kyron.bio is thrilled to announce our relocation to Hôpital Cochin, where we are now part of Paris Biotech Santé, the leading healthtech incubator in Paris.
This move not only places us at the heart of a thriving biotech ecosystem but also provides expanded lab space, enabling us to accelerate our R&D efforts and pursue new scientific avenues.
2025
Read more of
The seed funding round was led by HCVC, with the participation of Verve Ventures, Entrepreneur First, Saras Capital, and numerous reputable angel investors.
The funds will accelerate the development of kyron.bio’s proprietary glycan-engineering platform, expand the kyron.bio team and fuel preclinical studies.
2025